RPG Life Sciences & InvAscent
July 2026
Announced Date: July 2026
Value: USD 9 million
o3 Capital acted as the Exclusive Financial Advisor to RPG Life Sciences and InvAscent on their acquisition of Actis Generics
We are pleased to announce that our clients RPG Life Sciences and InvAscent have executed a Share Purchase Agreement for acquisition of 100% of the equity share capital of Actis Generics through RPG Life Sciences' subsidiary, RPG Active Pharma.
The transaction reinforces o3 Capital’s credentials in the Indian Life Sciences and Healthcare sector, where the firm has advised on 13 transactions over the past two years.
Speaking on the transaction, Shiraz Bugwadia, Managing Partner at o3 Capital, said: “Actis brings a differentiated position in complex API intermediates and a genuine cost advantage, which, alongside RPG Life Sciences' manufacturing depth and InvAscent's healthcare and pharma investing expertise, gives RPG Active Pharma a strong foundation to build from. We are pleased to have partnered with RPG Life Sciences and InvAscent on this acquisition and look forward to the high-quality API business they are set to build.”
Ashok Nair, Managing Director at RPG Life Sciences, said: “Building a meaningful and scalable presence in APIs has been a strategic priority for RPG Life Sciences. RPG Active Pharma gives us a focused business to pursue this opportunity with greater speed, discipline and scale. We are pleased to partner with InvAscent, whose pharma investing experience and long-term partnership approach complements our vision for the business. The proposed acquisition of Actis Generics further strengthens this business and supports our ambition to build a high-quality API business with expanded manufacturing capabilities, a broader product portfolio and the ability to create sustainable value for all stakeholders.”
Dr. Jeevak Gupta, Managing Director at InvAscent, said: “We are excited to partner with RPG Life Sciences in building RPG Active Pharma into a differentiated API business. RPG Life Sciences has established pharmaceutical capabilities, a strong operating foundation and a clear ambition to scale its API business. We believe RPG Active Pharma is well positioned to benefit from the long-term growth opportunity in high-quality API manufacturing, and we look forward to supporting the business through capital, strategic guidance and our healthcare sector experience.”
RPG Life Sciences, part of RPG Group, is an integrated, research-based pharmaceutical company operating in domestic and international markets across branded formulations, global generics and synthetic APIs.
RPG Active Pharma is a subsidiary of RPG Life Sciences focused on APIs, with an emphasis on product development, manufacturing excellence, portfolio expansion and serving domestic and export markets.
InvAscent, established in 2005, is one of India's leading healthcare-focused private equity firms with ~USD 850 million in capital raised to date and investments in 39 companies across pharmaceuticals, healthcare delivery, medical devices, animal health, nutraceuticals, and health tech.
Actis Generics, established in 2014 in Visakhapatnam, manufactures bulk drug intermediates and is a key supplier to leading API manufacturers in India. The company is well positioned in the supply chain for complex API intermediates, including Rivaroxaban, Sitagliptin and Apixaban, with a competitive cost advantage.
About o3 Capital
o3 Capital is a leading mid-market investment bank focused on delivering differentiated outcomes across private equity, M&A, structured finance, and strategic advisory. With deep sector expertise and long-standing client relationships, o3 Capital partners with entrepreneurs and institutions to drive transformational growth and value creation.
We are pleased to announce that our clients RPG Life Sciences and InvAscent have executed a Share Purchase Agreement for acquisition of 100% of the equity share capital of Actis Generics through RPG Life Sciences' subsidiary, RPG Active Pharma.
The transaction reinforces o3 Capital’s credentials in the Indian Life Sciences and Healthcare sector, where the firm has advised on 13 transactions over the past two years.
Speaking on the transaction, Shiraz Bugwadia, Managing Partner at o3 Capital, said: “Actis brings a differentiated position in complex API intermediates and a genuine cost advantage, which, alongside RPG Life Sciences' manufacturing depth and InvAscent's healthcare and pharma investing expertise, gives RPG Active Pharma a strong foundation to build from. We are pleased to have partnered with RPG Life Sciences and InvAscent on this acquisition and look forward to the high-quality API business they are set to build.”
Ashok Nair, Managing Director at RPG Life Sciences, said: “Building a meaningful and scalable presence in APIs has been a strategic priority for RPG Life Sciences. RPG Active Pharma gives us a focused business to pursue this opportunity with greater speed, discipline and scale. We are pleased to partner with InvAscent, whose pharma investing experience and long-term partnership approach complements our vision for the business. The proposed acquisition of Actis Generics further strengthens this business and supports our ambition to build a high-quality API business with expanded manufacturing capabilities, a broader product portfolio and the ability to create sustainable value for all stakeholders.”
Dr. Jeevak Gupta, Managing Director at InvAscent, said: “We are excited to partner with RPG Life Sciences in building RPG Active Pharma into a differentiated API business. RPG Life Sciences has established pharmaceutical capabilities, a strong operating foundation and a clear ambition to scale its API business. We believe RPG Active Pharma is well positioned to benefit from the long-term growth opportunity in high-quality API manufacturing, and we look forward to supporting the business through capital, strategic guidance and our healthcare sector experience.”
RPG Life Sciences, part of RPG Group, is an integrated, research-based pharmaceutical company operating in domestic and international markets across branded formulations, global generics and synthetic APIs.
RPG Active Pharma is a subsidiary of RPG Life Sciences focused on APIs, with an emphasis on product development, manufacturing excellence, portfolio expansion and serving domestic and export markets.
InvAscent, established in 2005, is one of India's leading healthcare-focused private equity firms with ~USD 850 million in capital raised to date and investments in 39 companies across pharmaceuticals, healthcare delivery, medical devices, animal health, nutraceuticals, and health tech.
Actis Generics, established in 2014 in Visakhapatnam, manufactures bulk drug intermediates and is a key supplier to leading API manufacturers in India. The company is well positioned in the supply chain for complex API intermediates, including Rivaroxaban, Sitagliptin and Apixaban, with a competitive cost advantage.
About o3 Capital
o3 Capital is a leading mid-market investment bank focused on delivering differentiated outcomes across private equity, M&A, structured finance, and strategic advisory. With deep sector expertise and long-standing client relationships, o3 Capital partners with entrepreneurs and institutions to drive transformational growth and value creation.